RxDoctor Payments Data

Michael Septer, DO

Family Medicine · Grand Rapids, MINPI 1013908060

Payments from drug & device makers

$14,510in general payments, 2019–2025

Across 989 payments — averaging $14.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • GSK$1K
  • Novo Nordisk$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Boehringer Ingelheim$926
  • plus $6K from 49 others

What the payments were for

  • Food & beverage$14,24298%
  • Education$2682%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,510 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$39,996
Medicare patients
34
Services billed
2,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide198$199,743
VraylarCariprazine Hcl71$101,722
LinzessLinaclotide71$53,073
EliquisApixaban43$35,388
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,104$21,673
TrulicityDulaglutide24$21,477
RexultiBrexpiprazole14$18,567
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,292
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl94$15,641
FarxigaDapagliflozin Propanediol18$15,182
JardianceEmpagliflozin19$14,568
SymbicortBudesonide/Formoterol Fumarate25$9,718
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine417$8,574
Albuterol Sulfate HfaAlbuterol Sulfate139$7,891
Testosterone Cypionate211$4,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,021$199,743198 claims
AbbVieVraylar, Linzess$2,716$154,795142 claims
PfizerEliquis$572$35,38843 claims
AstraZenecaFarxiga, Symbicort$892$24,90043 claims
Lilly USA, LLCTrulicity$484$21,47724 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,019$18,56714 claims
GSKTrelegy Ellipta$1,119$16,29217 claims
Boehringer IngelheimJardiance$926$14,56819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →